Alivus Life — Q1 FY26 earnings call

Call held 2 Aug 2025

Management summary

Alivus Life delivered a resilient Q1 FY26 performance characterized by significant margin expansion despite moderate top-line growth. The company successfully navigated a sharp decline in its business with former parent Glenmark (GPL) through strong 14.5% growth in its external (non-GPL) business. Management is pivoting toward a higher-margin CDMO and specialty API mix, backed by a robust pipeline and successful regulatory outcomes at key manufacturing sites.

Highlights

  • Revenue reported at ₹602 crores, representing a 2.2% YoY growth.

  • Gross margin expanded by 400 bps YoY to 55.1%, driven by rationalized input costs.

  • EBITDA margin stood at 30.1%, up 210 bps YoY, with EBITDA growth of 9.9%.

  • Non-GPL business grew 14.5% YoY, offsetting a 22% decline in the GPL (Glenmark) business.

  • Chronic therapies continue to dominate the portfolio, contributing 70% to the top line.

  • Company remains net debt-free with cash and cash equivalents of ₹660 crores.

  • Successful US FDA inspections at Dahej and Ankleshwar facilities with NAI classification.

  • Guidance maintained for mid-teens volume growth and high single-digit revenue growth for FY26.

Concerns

  • Pricing Pressure in API Market

Key financials

  1. Revenue ₹602 Cr +2.2%YoY
  2. Gross Margin 55.1%
  3. EBITDA Margin 30.1%
  4. PAT ₹122 Cr
  5. R&D Spend ₹21 Cr
  6. Cash Balance ₹660 Cr

What they filed

Q1 FY27: revenue up 6.3%, net profit up 31.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue507 642 650 602 588 +16%673 +5%689 +6%640 +6%
EBITDA134 190 198 172 179 +34%231 +22%215 +9%212 +23%
Net profit95 137 142 122 130 +37%150 +9%163 +15%160 +31%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Non-GPL Business
    14.5% Revenue Growth18% Volume Growth
  • GPL Business
    -22% Revenue Growth
  • Generic API
    3% Revenue Growth-7.1% Revenue Growth

Guidance & targets

Volume

  • Volume Growth Volume · FY26 · High confidence mid-teens
    Looking ahead, we maintain our earlier guidance of mid-teens volume growth for FY ‘26.

    — Dr. Yasir Rawjee, MD and CEO

Revenue

  • Revenue Growth Revenue · FY26 · Medium confidence high single digits
    However, due to pricing pressures, revenue growth is expected to remain in the high single digits.

    — Dr. Yasir Rawjee, MD and CEO

Margin

  • EBITDA Margin Band Margin · foreseeable future · High confidence 28% to 30%
    We would like to reiterate that margins will continue to be in the 28% to 30% band in the foreseeable future.

    — Dr. Yasir Rawjee, MD and CEO

Capex

  • Total Capex Capex · FY26 · High confidence ₹600 crores
    Capex guidance, we have a capex approval from the Board of INR600 crores including carryover of INR190 crores from FY '25.

    — Tushar Mistry, CFO

Market Share

  • CDMO Revenue Contribution Market Share · 4 to 5 years · Medium confidence 12% to 15%

    From 6% to 7% today

    So if you recall, right, we had said that today, it's about 6%, 7%, but we'll take it to around 12% to 15%, in 4 to 5 years' time.

    — Dr. Yasir Rawjee, MD and CEO

Other

  • R&D Spend as % of Revenue Other · FY26 · High confidence 4% to 4.5%

    From 3.5% today

    Going forward, I mean, I don't think it will exceed 4% to 4.5% of revenue.

    — Dr. Yasir Rawjee, MD and CEO

Risks & concerns

  • Pricing Pressure in API Market

    high

    Management noted that while volume growth is mid-teens, revenue growth is capped at high single digits due to pricing headwinds.

    Management acknowledged

  • Inventory Rationalization by GPL

    medium

    The 22% YoY decline in the GPL segment impacted overall generic API growth, though recovery is expected in H2.

    Both acknowledged

  • CDMO Project Lumpiness

    medium

    CDMO business remained subdued in Q1; growth is dependent on the commercialization of the 5th project in H2.

    Management acknowledged

Areas of evasion (2)

  • Specific product concentration percentages (provided as a guess)
  • Exact timing of inorganic acquisitions

Q&A highlights

2 direct
Glenmark (GPL) Business Decline Direct
There is waviness in the demand pattern from GPL. We expect that GPL business will also grow, okay? And so, we are pretty confident that, this high single-digit growth overall that we are forecasting is very likely to happen.

Clarifies that the 22% decline in GPL business is a temporary inventory rationalization issue rather than a structural loss of business.

Asked by Ahmed Madha, Unifi Capital

High-Potent API Pipeline Commercialization Direct
12 already have got firm customer interest and that's why we are validating... we should see commercial activity on our onco pipeline, on our high-potent pipeline from late FY ’27.

Provides a specific timeline for the next major growth leg in the specialty API segment.

Asked by Tarang Agrawal, Old Bridge

Long-term Profitability Target Partial
Double in 5 years... We could be close, but let's see.

Management signals an aspirational goal to reach ~₹1,000 crores in net profit within 5 years, implying a ~15% CAGR.

Asked by Ketan Chheda, Individual Investor

2 min read 5 chapters

Detailed narrative

Non-GPL Business Offsets Glenmark Rationalization

Alivus Life reported a 2.2% YoY revenue growth to ₹602 crores, a figure that masks a significant shift in business mix. The external (non-GPL) business grew by 14.5% YoY and 18% in volume terms, effectively counteracting a 22% decline in business from former parent Glenmark. Management attributed the GPL decline to inventory rationalization and expressed confidence that this segment would recover in the second half of the year, maintaining a high single-digit growth target for the full year.

Margin Resilience Despite Pricing Pressures

The company achieved a stellar gross margin of 55.1%, up 400 bps YoY, and an EBITDA margin of 30.1%. This expansion was driven by rationalized input costs, better energy efficiency, and the successful launch of new products with higher margins. Despite acknowledging pricing pressures in the broader API market that will likely limit revenue growth to high single digits, management reiterated that EBITDA margins will remain sustainable in the 28% to 30% band.

CDMO Ramp-up Expected in H2 FY26

The CDMO segment remained subdued during Q1, but management anticipates a broader ramp-up in H2 FY26. Validation batches for the fifth major CDMO project have commenced, with commercialization expected in the second half. Long-term, Alivus aims to double the CDMO contribution to 12-15% of total revenue over the next 4-5 years, up from the current 6-7% level, citing high confidence due to an increasing project pipeline.

Strategic Capacity Expansion at Solapur

The Solapur facility is on track to begin operations in Q4 FY26. Initially, a significant portion of this capacity will be used for backward integration to improve the bottom line, with ROW (Rest of World) business expected to start in the first half of next year. The company has a total capex approval of ₹600 crores for FY26, which includes brownfield projects at Dahej and Ankleshwar to support the growing CDMO and specialty API demand.

Regulatory De-risking with Successful FDA Inspections

A major highlight of the quarter was the successful US FDA inspection of the Dahej facility, which received an EIR with NAI (No Action Indicated) classification. This follows a similar successful inspection at the Ankleshwar facility earlier in the year. These outcomes are significant as both large facilities had not been audited for nearly six years, effectively removing a major regulatory overhang for the company.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls